eyeforpharma Barcelona day oneDay one: Tuesday 12 March Highlights include: Brent Saunders, CEO of Allergan, discusses the biggest challenges for the Share Xeyeforpharma Barcelona day onehttps://pharmaphorum.com/event-coverage/eyeforpharma-barcelona-2019-day-1/
Curious2018: A thirst for innovationAll too often pharma companies are accused of putting shareholders before their patients and society as a whole. Share XCurious2018: A thirst for innovationhttps://pharmaphorum.com/views-and-analysis/curious2018-innovation-thirst/
Oncolytics: the dawn of a new era in cancer treatmentOncolytic virus therapy is not a new discovery, but it may now be positioned as the next major Share XOncolytics: the dawn of a new era in cancer treatmenthttps://pharmaphorum.com/views-analysis-oncology/oncolytics-new-era-cancer-treatment/
Exclusive Live coverage: Curious2018 Future Insight: Day 3Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share XExclusive Live coverage: Curious2018 Future Insight: Day 3https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-3/
Exclusive Live coverage: Curious2018 Future Insight: Day 2Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share XExclusive Live coverage: Curious2018 Future Insight: Day 2https://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-two/
Exclusive Live coverage: Curious2018 – Future Insight: Day OneCurious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some Share XExclusive Live coverage: Curious2018 – Future Insight: Day Onehttps://pharmaphorum.com/views-and-analysis/exclusive-live-coverage-curious2018-future-insight-day-one/
Raising the bar in liver cancer therapypharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint comboBreast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share XASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combohttps://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/OMerck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow Share XASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/Ohttps://pharmaphorum.com/event-coverage/asco-2018-bms-merck-co-locks-out-lung-cancer-i-o/
ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and moreBristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Share XASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and morehttps://pharmaphorum.com/views-analysis-oncology/asco_2018-opdivo-nektar-abbvies-leukaemia/
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerThe American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance Share XASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerhttps://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/
